Vicore's ASPIRE IPF Trial Clears Futility Analysis, Stays on Track for Mid-2027 Data
VCRE sits 33% above its 52-week low of $7.88 on elevated volume (5.1× avg).
Summary
Vicore's Phase 2b ASPIRE trial of buloxibutid in IPF passed its pre-planned futility analysis, with the iDMC recommending it continue unchanged and flagging no safety concerns. The 378-patient trial remains on track for 52-week topline results in mid-2027.
Key Events · Product Development and Regulatory · VCRE
-
ASPIRE Passes Futility Analysis
The independent Data Monitoring Committee recommended the Phase 2b ASPIRE trial of buloxibutid in IPF continue without modification; the pre-specified futility criteria were not met.
-
No Safety Concerns Raised
In its regular safety and benefit-risk review of all available data, the iDMC raised no concerns.
-
Analysis Covered ~27% of Patients
The futility check used efficacy data from approximately the first 100 randomized patients who completed 52 weeks or discontinued, about 27% of the 378 enrolled, with a conditional power threshold of 20%.
-
Company Still Blinded to Data
No quantitative results — treatment-effect estimates or conditional power values — were disclosed to Vicore, so efficacy remains unknown until the readout.
Analysis · VCRE · Life Sciences
The independent Data Monitoring Committee reviewed 52-week lung-function data from the first ~100 patients and decided ASPIRE should keep going as designed. The pre-specified futility bar — conditional power below 20% — was not hit, and no safety concerns were raised. That removes the near-term risk of the program being stopped early, which for a clinical-stage company whose lead asset is buloxibutid is the main thing that could have collapsed the story. Nothing about efficacy is actually known: Vicore stays blinded and disclosed no treatment-effect or conditional-power numbers, so the real test is the 52-week topline in mid-2027. Cash runway into the second half of 2028 is stated to extend past that readout, so no financing is forced before the data.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 29.3% of the 1526 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VCRE was trading at $10.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $260.3M. The 52-week trading range was $7.88 to $17.80. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.